Heron Therapeutics, Inc.
HRTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000818033
No open-market purchases or sales by Heron Therapeutics, Inc. insiders were filed in the last 90 days; 163 institutions reported holding it in 13F filings for Q2 2026, worth $57.2M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Heron Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Heron Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hensley Mark Earl | Chief Operating Officer | 170,901 | Aug 10, 2026 | 5 |
| Forbes William P | EVP, Chief Development Officer | 241,173 | Aug 3, 2026 | 10 |
| Duarte Ira | EVP, Chief Financial Officer | 281,899 | Aug 3, 2026 | 10 |
| Collard Craig A | Chief Executive Officer | 856,492 | Aug 3, 2026 | 10 |
| Johnson Craig A | Director | 53,960 | Feb 3, 2026 | 1 |
| Christian Waage | Director | 53,960 | Feb 3, 2026 | 1 |
| Kaseta Michael | Director | 53,960 | Feb 3, 2026 | 1 |
| Dissanaike Sharmila | Director | 53,960 | Feb 3, 2026 | 1 |
| Morgan Adam | Director | 123,737 | Feb 3, 2026 | 1 |
| Cusack Thomas | Director | 53,960 | Feb 3, 2026 | 2 |
| Rubric Capital Management LP | 10% Owner | 30,046,828Indirect | Oct 17, 2025 | 1 |
| Rosen David Efraim | 10% Owner | 30,046,828Indirect | Oct 17, 2025 | 1 |
| Rodriguez Susan | Director | 87,180 | Feb 4, 2025 | 0 |
| Peraza Lisa | VP, Chief Accounting Officer | 55,907 | Jan 19, 2024 | 0 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 33,754 | Jul 17, 2023 | 0 |
| Manhard Kimberly | EVP, Drug Development | 28,330 | Apr 17, 2023 | 0 |
| Poyhonen John | President & CCO | 46,648 | Apr 17, 2023 | 0 |
| Quart Barry D | Chief Executive Officer | 177,989 | Jan 20, 2023 | 0 |
| Davis Stephen | Director | 52,032 | Dec 20, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2025 (view filing)6:00 PM ET | Aug 8 | 4 days | Rubric Capital Management LP and 1 other10% Owner | PPurchaseCommon Stock, par value $0.01 per share ("Common Stock") | +2.39M | $1.50 | +$3.58M | +8.9%29.1M after | |
| Aug 12, 2025 (view filing)6:00 PM ET | Aug 8 | 4 days | Rubric Capital Management LP and 1 other10% Owner | PPurchaseConvertible Senior Unsecured Promissory Notes ("Notes") | – | – | – | – | DerivativePrice outlier |
| Aug 12, 2025 (view filing)6:00 PM ET | Aug 8 | 4 days | Rubric Capital Management LP and 1 other10% Owner | PPurchase | +946.1K | $1.50 | +$1.42M | –94.6K after | Derivative |
| Aug 12, 2025 (view filing) | Aug 8 | 4 days | Morgan AdamDirector | PPurchase | +1.77M | $1.50 | +$2.65M | +25.3%8.75M after | |
| Aug 12, 2025 (view filing) | Aug 8 | 4 days | Morgan AdamDirector | PPurchase | +700.1K | $1.50 | +$1.05M | –70.0K after | Derivative |
| Nov 21, 2023 (view filing) | Nov 17 | 4 days | Forbes William PEVP, Chief Development Officer | PPurchase | +25.0K | $1.09 | +$27.3K | +46.3%79.0K after | |
| Nov 20, 2023 (view filing) | Nov 16 | 4 days | Forbes William PEVP, Chief Development Officer | PPurchase | +50.0K | $0.94 | +$47.0K | +1,250.0%54.0K after | |
| Nov 17, 2023 (view filing) | Nov 16 | 1 day | Collard Craig AChief Executive Officer | PPurchase | +150.0K | $0.92 | +$138.0K | +411.0%186.5K after | |
| Nov 17, 2023 (view filing) | Nov 16 | 1 day | Duarte IraEVP, Chief Financial Officer | PPurchase | +85.0K | $0.89 | +$75.7K | New position85.0K after | |
| Jul 25, 2023 (view filing) | Jul 21 | 4 days | Morgan AdamDirector | PPurchaseCommon Stock, par value $0.01 per share | +2.49M | $1.37 | +$3.41M | +55.3%6.99M after | |
| Jul 25, 2023 (view filing) | Jul 21 | 4 days | Morgan AdamDirector | PPurchaseCommon Stock, par value $0.01 per share | +1.16M | $1.37 | +$1.59M | –1.16M after | Derivative |
| May 4, 2022 (view filing) | May 3 | 1 day | Manhard KimberlyEVP, Drug Development | SSale | −1.50K | $4.76 | −$7.16K | −12.2%10.9K after | |
| Dec 23, 2021 (view filing) | Dec 21 | 2 days | Christian WaageDirector | SSale | −300 | $9.73 | −$2.92K | −8.6%3.20K after | |
| Dec 23, 2021 (view filing) | Dec 21 | 2 days | Johnson Craig ADirector | SSale | −250 | $9.73 | −$2.43K | −8.1%2.84K after | |
| Sep 23, 2021 (view filing) | Sep 21 | 2 days | Christian WaageDirector | SSale | −300 | $12.31 | −$3.69K | −7.9%3.50K after | |
| Sep 23, 2021 (view filing) | Sep 21 | 2 days | Johnson Craig ADirector | SSale | −250 | $12.30 | −$3.08K | −7.5%3.09K after |